Catherine A. Hayes’s research while affiliated with University of Mississippi Medical Center and other places

What is this page?


This page lists works of an author who doesn't have a ResearchGate profile or hasn't added the works to their profile yet. It is automatically generated from public (personal) data to further our legitimate goal of comprehensive and accurate scientific recordkeeping. If you are this author and want this page removed, please let us know.

Publications (2)


Behavioral Pharmacology of Sedatives, Hypnotics, and Anxiolytics
  • Chapter

January 1998

·

12 Reads

·

1 Citation

·

Catherine A. Hayes

·

The purpose of this chapter is to review the behavioral pharmacology and abuse liability of commonly prescribed anxiolytics and hypnotics. More specifically, this chapter reviews the behavioral pharmacology and abuse liability of commonly prescribed benzodiazepines (e.g., alprazolam, diazepam, estazolam, lorazepam, temazepam, and triazolam) and nonbenzodiazepine anxiolytics-hypnotics (e.g., buspirone and zolpidem). The behavioral pharmacology and abuse liability of the benzodiazepines is not exhaustively reviewed since such a review is beyond the scope of this chapter, and comprehensive reviews have previously been published (Woods, Katz, & Winger, 1987, 1992). Instead, this chapter focuses on studies that attempted to determine putative differences between benzodiazepines. This chapter then reviews the behavioral pharmacology and abuse liability of two nonbenzodiazepine compounds marketed for the treatment of anxiety and sleep disorders: buspirone and zolpidem, respectively. Buspirone was the first pyrimidinylpiperazine derivative marketed for the treatment of anxiety disorders, while zolpidem was the first imidazopyridine derivative marketed for the treatment of sleep disorders. Only studies that directly compared these drugs with a benzodiazepine are reviewed in an attempt to determine if these nonbenzodiazepine compounds have an improved abuse liability profile. Both nonhuman and human studies are reviewed.


Trazodone and triazolam: Acute subject rated and performance-impairing effects in healthy volunteers

June 1997

·

75 Reads

·

28 Citations

Psychopharmacology

·

Sudhakar Madakasira

·

Catherine A. Hayes

·

[...]

·

The present study compared the acute subject-rated and performance-impairing effects of trazodone and triazolam in seven healthy humans. Trazodone (50, 100 and 200 mg), triazolam (0.125, 0.25, 0.50 mg) and placebo were administered orally in a double-blind, crossover design. Drug effects were measured approximately 30 min before drug administration and repeatedly afterwards for 6 h. Trazodone and triazolam produced dose-related increases in subject-ratings of drug effect and sedation. The absolute magnitude of trazodone's and triazolam's effects was comparable across these measures, which suggests the doses tested were equivalent on some behavioral dimension. By contrast, triazolam, but not trazodone, increased subject ratings of "dizzy", "excited", "nervous", "restless", "stomach turning" and "itchy skin". Triazolam, but not trazodone, significantly impaired learning, recall and performance. The present findings suggest trazodone may be a viable alternative to benzodiazepine hypnotics like triazolam, especially when needing to minimize drug-induced impairment. Future research could extend the present findings by replicating them in a clinically relevant population such as individuals with histories of drug abuse.

Citations (2)


... However, comparing the effect of testosterone with that of highly addictive drugs, it is clear that testosterone is substantially less reinforcing than cocaine or heroin. Instead, the reward potential for androgen may be comparable to that of benzodiazepines, caffeine or nicotine [23][24][25]. ...

Reference:

Oral Testosterone Self-Administration in Male Hamsters
Behavioral Pharmacology of Sedatives, Hypnotics, and Anxiolytics
  • Citing Chapter
  • January 1998

... Reports in normal volunteers and subjects with a history of drug abuse comparing trazodone, triazolam and zolpidem seem to suggest that trazodone (dose range 100-300 mg) may have less potential for misuse among prior drug abusers [89]. Trazodone also had less performance-impairing effects, although it should be noted that these were acute studies of daytime administration [90]. ...

Trazodone and triazolam: Acute subject rated and performance-impairing effects in healthy volunteers
  • Citing Article
  • June 1997

Psychopharmacology